Publication details
Apremilast - výhody šetrné léčby psoriázy
| Authors | |
|---|---|
| Year of publication | 2018 |
| Type | Conference abstract |
| Citation | |
| Description | Apremilast is a small phosphodiesterase 4 (PDE 4) inhibitor molecule that modulates the network of pro and anti-inflammatory cytokines in the nukleus of various cells. Treatment with apremiast is suitable for psoriatic patients with PASI> 10 who have already undergone classical systemic therapy, which they have not tolerated or it has not been sufficiently effective. Preferably, apremilast can also be used in patients at risk of infections, immunosuppressed or oncologic individuals, in elderly patients with multiple concomitant medications or in obese patients with many comorbidities. Apremilast is a small phosphodiesterase 4 (PDE 4) inhibitor molecule that modulates the network of pro and anti-inflammatory cytokines in the nukleus of various cells. Treatment with apremiast is suitable for psoriatic patients with PASI> 10 who have already undergone classical systemic therapy, which they have not tolerated or it has not been sufficiently effective. Preferably, apremilast can also be used in patients at risk of infections, immunosuppressed or oncologic individuals, in elderly patients with multiple concomitant medications or in obese patients with many comorbidities. |